Annual Accounts Receivable
$60.14 M
+$8.09 M+15.54%
31 December 2023
Summary:
Heron Therapeutics annual accounts receivable is currently $60.14 million, with the most recent change of +$8.09 million (+15.54%) on 31 December 2023. During the last 3 years, it has risen by +$18.29 million (+43.70%). HRTX annual accounts receivable is now -6.98% below its all-time high of $64.65 million, reached on 31 December 2018.HRTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$67.04 M
-$6.67 M-9.05%
30 September 2024
Summary:
Heron Therapeutics quarterly accounts receivable is currently $67.04 million, with the most recent change of -$6.67 million (-9.05%) on 30 September 2024. Over the past year, it has increased by +$3.24 million (+5.09%). HRTX quarterly accounts receivable is now -12.59% below its all-time high of $76.69 million, reached on 30 June 2023.HRTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +15.5% | +5.1% |
| 3 y3 years | +43.7% | +55.6% |
| 5 y5 years | -7.0% | +0.1% |
HRTX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +69.4% | -12.6% | +88.8% |
| 5 y | 5 years | -7.0% | +69.4% | -12.6% | +99.2% |
| alltime | all time | -7.0% | -12.6% |
Heron Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $67.04 M(-9.0%) |
| June 2024 | - | $73.71 M(+12.8%) |
| Mar 2024 | - | $65.32 M(+8.6%) |
| Dec 2023 | $60.14 M(+15.5%) | $60.14 M(-5.7%) |
| Sept 2023 | - | $63.80 M(-16.8%) |
| June 2023 | - | $76.69 M(+49.1%) |
| Mar 2023 | - | $51.45 M(-1.2%) |
| Dec 2022 | $52.05 M(+46.6%) | $52.05 M(+23.4%) |
| Sept 2022 | - | $42.19 M(+4.7%) |
| June 2022 | - | $40.30 M(-1.9%) |
| Mar 2022 | - | $41.10 M(+15.8%) |
| Dec 2021 | $35.50 M(-15.2%) | $35.50 M(-17.6%) |
| Sept 2021 | - | $43.09 M(+1.1%) |
| June 2021 | - | $42.62 M(+10.6%) |
| Mar 2021 | - | $38.52 M(-7.9%) |
| Dec 2020 | $41.85 M(+4.9%) | $41.85 M(+24.4%) |
| Sept 2020 | - | $33.65 M(-10.3%) |
| June 2020 | - | $37.50 M(+7.7%) |
| Mar 2020 | - | $34.81 M(-12.7%) |
| Dec 2019 | $39.88 M(-38.3%) | $39.88 M(-40.4%) |
| Sept 2019 | - | $66.95 M(+0.2%) |
| June 2019 | - | $66.82 M(-9.7%) |
| Mar 2019 | - | $74.01 M(+14.5%) |
| Dec 2018 | $64.65 M(+54.4%) | $64.65 M(+20.5%) |
| Sept 2018 | - | $53.63 M(+16.9%) |
| June 2018 | - | $45.89 M(+21.7%) |
| Mar 2018 | - | $37.71 M(-9.9%) |
| Dec 2017 | $41.87 M(+2036.4%) | $41.87 M(+45.1%) |
| Sept 2017 | - | $28.85 M(+55.0%) |
| June 2017 | - | $18.62 M(+80.3%) |
| Mar 2017 | - | $10.33 M(+426.9%) |
| Dec 2016 | $1.96 M(>+9900.0%) | $1.96 M(>+9900.0%) |
| Dec 2015 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2011 | - | $0.00(0.0%) |
| June 2011 | - | $0.00(-100.0%) |
| Mar 2011 | - | $261.00 K(+137.3%) |
| Dec 2010 | $110.00 K | $110.00 K(-66.5%) |
| Sept 2010 | - | $328.00 K(-7.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2010 | - | $356.00 K(+58.9%) |
| Mar 2010 | - | $224.00 K(+31.0%) |
| Dec 2009 | $171.00 K(+434.4%) | $171.00 K(-64.8%) |
| Sept 2009 | - | $486.00 K(+4318.2%) |
| June 2009 | - | $11.00 K(+37.5%) |
| Mar 2009 | - | $8000.00(-75.0%) |
| Dec 2008 | $32.00 K(-78.9%) | $32.00 K(0.0%) |
| Sept 2008 | - | $32.00 K(-78.9%) |
| June 2008 | - | $152.00 K(+14.3%) |
| Mar 2008 | - | $133.00 K(-12.5%) |
| Dec 2007 | $152.00 K(+102.7%) | $152.00 K(+21.6%) |
| Sept 2007 | - | $125.00 K(-10.1%) |
| June 2007 | - | $139.00 K(+11.2%) |
| Mar 2007 | - | $125.00 K(+66.7%) |
| Dec 2006 | $75.00 K(-95.1%) | $75.00 K(0.0%) |
| Sept 2006 | - | $75.00 K(0.0%) |
| June 2006 | - | $75.00 K(0.0%) |
| Mar 2006 | - | $75.00 K(-95.1%) |
| Dec 2005 | $1.52 M(+0.9%) | $1.52 M(+7.5%) |
| Sept 2005 | - | $1.41 M(+1.4%) |
| June 2005 | - | $1.39 M(-2.9%) |
| Mar 2005 | - | $1.44 M(-4.7%) |
| Dec 2004 | $1.51 M(+12.4%) | $1.51 M(+21.6%) |
| Sept 2004 | - | $1.24 M(-3.8%) |
| June 2004 | - | $1.29 M(-12.2%) |
| Mar 2004 | - | $1.47 M(+9.4%) |
| Dec 2003 | $1.34 M(0.0%) | $1.34 M(+5.8%) |
| Sept 2003 | - | $1.27 M(-5.5%) |
| June 2003 | - | $1.34 M(-3.2%) |
| Mar 2003 | - | $1.39 M(+3.4%) |
| Dec 2002 | $1.34 M(+296.4%) | $1.34 M(+314.9%) |
| Sept 2002 | - | $323.00 K(-8.8%) |
| June 2002 | - | $354.00 K(-5.0%) |
| Mar 2002 | - | $372.50 K(+10.2%) |
| Dec 2001 | $338.00 K(-80.0%) | $338.00 K(+55.5%) |
| Sept 2001 | - | $217.30 K(-40.1%) |
| June 2001 | - | $362.80 K(-7.1%) |
| Mar 2001 | - | $390.60 K(-76.9%) |
| Dec 2000 | $1.69 M | $1.69 M |
FAQ
- What is Heron Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Heron Therapeutics?
- What is Heron Therapeutics annual accounts receivable year-on-year change?
- What is Heron Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Heron Therapeutics?
- What is Heron Therapeutics quarterly accounts receivable year-on-year change?
What is Heron Therapeutics annual accounts receivable?
The current annual accounts receivable of HRTX is $60.14 M
What is the all time high annual accounts receivable for Heron Therapeutics?
Heron Therapeutics all-time high annual accounts receivable is $64.65 M
What is Heron Therapeutics annual accounts receivable year-on-year change?
Over the past year, HRTX annual accounts receivable has changed by +$8.09 M (+15.54%)
What is Heron Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of HRTX is $67.04 M
What is the all time high quarterly accounts receivable for Heron Therapeutics?
Heron Therapeutics all-time high quarterly accounts receivable is $76.69 M
What is Heron Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, HRTX quarterly accounts receivable has changed by +$3.24 M (+5.09%)